Faith Davies, MBBCh, MRCP, MD, FRCPath, is Professor of Medicine and Director of the Phase I Clinical Trials Program for both the Myeloma Institute for Research and Therapy and the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS). She is also Deputy Director of the Myeloma Institute.
Dr. Davies is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the treatment of relapsed refractory disease.
Dr. Davies came to UAMS in 2014 from the Institute of Cancer Research and the Royal Marsden Hospital, both in London. She earned her medical degree from the College of Medicine, University of Wales. She completed general medical training in Cardiff and Birmingham and hematology specialty training in Leeds and London.
Dr. Davies’s focus is on the biology and treatment of myeloma with an emphasis on potential new drugs and new genetic technologies and their applications to myeloma. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those laboratory findings into individualized treatment in the clinical setting.
Dr. Davies is a member of the British Society of Haematology, the American Society of Hematology, the American Association for Cancer Research, the Royal College of Physicians, UK, and the Royal College of Pathologists, UK.
Education and Training
- Medical School: MD, College of Medicine, University of Wales, United Kingdom
- General Medical Training completed in Cardiff and Birmingham, United Kingdom
- Hematology Specialty Training completed in Leeds and London, United Kingdom
- Multiple Myeloma
- Smoldering Myeloma
- Stem Cell Transplantation
- Waldenstrom Macroglobulinemia
- Phase I Clinical Trials
- Molecular Diagnostics